Physician profile
Elia Barraza
NPI 1245932458
$1,463.62
in general payments reported to CMS, 2019-2025
13 companies · $390 in 2025
The $390 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,074 · 2025: $390.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,218 · Education: $246.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,217.65 |
| Education | $245.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $339.93 | 2024 | Ingrezza |
| Astellas Pharma US INC | $197.16 | 2024 | Cresemba |
| Acadia Pharmaceuticals INC | $196.12 | 2024 | Nuplazid |
| Sk Life Science, INC. | $195.87 | 2024-2025 | Xcopri |
| Emd Serono, INC. | $169.46 | 2024 | Mavenclad |
| Biogen, INC. | $104.24 | 2024-2025 | Spinraza, Qalsody, Tysabri |
| Janssen Biotech, INC. | $95.86 | 2025 | |
| Alexion Pharmaceuticals, INC. | $49.02 | 2024-2025 | Ultomiris |
| Springworks Therapeutics, INC. | $33.23 | 2025 | Ogsiveo |
| Ani Pharmaceuticals, INC. | $26.54 | 2025 | Purified Cortrophin Gel |
| C2n Diagnostics, LLC | $23.32 | 2025 | Precivityad2 |
| Argenx US, INC. | $19.07 | 2024 | Vyvgart, Vyvgart Hytrulo |
| Lilly USA, LLC | $13.80 | 2024 | Kisunla, Amyvid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elia Barraza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.